Covid19 Clinical Trial
Official title:
Pregnancy Outcomes According to the Gestational Age of Acquiring COVID-19 : an International Case-control Study
| Verified date | September 2021 |
| Source | Brugmann University Hospital |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
A new coronavirus, called severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) appeared in Wuhan, China and it arrived to Europe 2-3 months later. It infected millions of persons and led to the death of thousands until May 2020 where numbers of infections per week decreased significantly. However, starting September, number of infections started to escalate again and continued to rise until now. Hundreds of good quality articles were published during this period to study the relationship and effects of this virus on pregnancy and vice versa, as well as to determine the adverse neonatal and obstetrical outcomes following the infection. In a case-control study using propensity score matching at the level of age, body mass index and comorbidities (diabetes, hypertension, asthma), pregnant women over 20 week's gestation had significantly higher risk for intensive care unit stay, endotracheal intubation, hospitalization for disease related symptoms and need for oxygen therapy. A new systematic review also demonstrated increased risk for ICU admission in pregnant women compared to non-pregnant women and to non-infected pregnant women. On the other hand, many researchers have demonstrated that the rates of preterm delivery and cesarean delivery have increased as well, others reported a close relation between SARS-CoV2 infection and preeclampsia or preeclampsia like condition. Enormous effort was done in order to understand adverse outcomes related to this infection, however, most studies included patients in the third or late second trimester. Few studies stratified adverse outcomes of the patients according to the trimester of infection.
| Status | Completed |
| Enrollment | 10925 |
| Est. completion date | September 1, 2021 |
| Est. primary completion date | September 1, 2021 |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: Pregnant women with viable fetus after 10 weeks' gestation and known pregnancy outcome during the period starting on February 1st 2020 and ending on November 30th 2020. Exclusion Criteria: All ongoing pregnancies, those with unknown outcomes, those terminated medically or voluntary, as well as patients with spontaneous abortion before the 11th gestational week. |
| Country | Name | City | State |
|---|---|---|---|
| Belgium | CHU Brugmann | Brussels | |
| France | Antoine Béclère Hospital | Clamart | |
| France | Hôpital Louis Mourier | Colombes | |
| Italy | Fondazione Policlinico Universitario Agostino Gemelli | Roma |
| Lead Sponsor | Collaborator |
|---|---|
| Brugmann University Hospital |
Belgium, France, Italy,
Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, Debenham L, Llavall AC, Dixit A, Zhou D, Balaji R, Lee SI, Qiu X, Yuan M, Coomar D, Sheikh J, Lawson H, Ansari K, van Wely M, van Leeuwen E, Kostova E, Kunst H, Khalil A, Tiberi S, Brizuela V, Broutet N, Kara E, Kim CR, Thorson A, Oladapo OT, Mofenson L, Zamora J, Thangaratinam S; for PregCOV-19 Living Systematic Review Consortium. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020 Sep 1;370:m3320. doi: 10.1136/bmj.m3320. — View Citation
Badr DA, Mattern J, Carlin A, Cordier AG, Maillart E, El Hachem L, El Kenz H, Andronikof M, De Bels D, Damoisel C, Preseau T, Vignes D, Cannie MM, Vauloup-Fellous C, Fils JF, Benachi A, Jani JC, Vivanti AJ. Are clinical outcomes worse for pregnant women at =20 weeks' gestation infected with coronavirus disease 2019? A multicenter case-control study with propensity score matching. Am J Obstet Gynecol. 2020 Nov;223(5):764-768. doi: 10.1016/j.ajog.2020.07.045. Epub 2020 Jul 27. — View Citation
Berghella V, Boelig R, Roman A, Burd J, Anderson K. Decreased incidence of preterm birth during coronavirus disease 2019 pandemic. Am J Obstet Gynecol MFM. 2020 Nov;2(4):100258. doi: 10.1016/j.ajogmf.2020.100258. Epub 2020 Oct 15. — View Citation
Cosma S, Carosso AR, Cusato J, Borella F, Carosso M, Bovetti M, Filippini C, D'Avolio A, Ghisetti V, Di Perri G, Benedetto C. Coronavirus disease 2019 and first-trimester spontaneous abortion: a case-control study of 225 pregnant patients. Am J Obstet Gynecol. 2021 Apr;224(4):391.e1-391.e7. doi: 10.1016/j.ajog.2020.10.005. Epub 2020 Oct 8. — View Citation
Khalil A, von Dadelszen P, Draycott T, Ugwumadu A, O'Brien P, Magee L. Change in the Incidence of Stillbirth and Preterm Delivery During the COVID-19 Pandemic. JAMA. 2020 Jul 10. doi: 10.1001/jama.2020.12746. [Epub ahead of print] — View Citation
Mendoza M, Garcia-Ruiz I, Maiz N, Rodo C, Garcia-Manau P, Serrano B, Lopez-Martinez RM, Balcells J, Fernandez-Hidalgo N, Carreras E, Suy A. Pre-eclampsia-like syndrome induced by severe COVID-19: a prospective observational study. BJOG. 2020 Oct;127(11):1374-1380. doi: 10.1111/1471-0528.16339. Epub 2020 Jun 21. — View Citation
Prabhu M, Cagino K, Matthews KC, Friedlander RL, Glynn SM, Kubiak JM, Yang YJ, Zhao Z, Baergen RN, DiPace JI, Razavi AS, Skupski DW, Snyder JR, Singh HK, Kalish RB, Oxford CM, Riley LE. Pregnancy and postpartum outcomes in a universally tested population for SARS-CoV-2 in New York City: a prospective cohort study. BJOG. 2020 Nov;127(12):1548-1556. doi: 10.1111/1471-0528.16403. Epub 2020 Aug 13. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Preterm delivery | Delivery at a gestational age < 37 weeks | 5 minutes | |
| Primary | Preeclampsia | Preeclampsia is defined as elevated blood pressure (Systolic blood pressure =140 mmHg or diastolic blood pressure =90 mmHg on at least 2 occasions at least 4 hours apart after 20 weeks of gestation in a previously normotensive patient) and the new onset of 1 or more of the following:
Proteinuria =0.3 g in a 24-hour urine specimen or protein/creatinine ratio =0.3 (mg/mg) (30 mg/mmol) in a random urine specimen or dipstick =2+ if a quantitative measurement is unavailable Platelet count <100,000/microL Serum creatinine >1.1 mg/dL (97.2 micromol/L) or doubling of the creatinine concentration in the absence of other renal disease Liver transaminases at least twice the upper limit of the normal concentrations for the local laboratory Pulmonary edema New-onset and persistent headache not accounted for by alternative diagnoses and not responding to usual doses of analgesics Visual symptoms (eg, blurred vision, flashing lights or sparks, scotomata) |
5 minutes | |
| Primary | Eclampsia | Eclampsia is defined by the occurrence of a grand mal seizure in a woman with preeclampsia in the absence of other neurologic conditions that could cause seizure. | 5 minutes | |
| Primary | Hemolysis Elevated Liver enzymes Low Platelets Syndrome (HELLP) | HELLP syndrome is considered to be a serious complication or variant of preeclampsia in pregnant women. | 5 minutes | |
| Primary | Number of participants with Cesarean delivery (CD) | Number of participants with Cesarean delivery (CD) | 5 minutes | |
| Primary | Percentage of participants with Cesarean delivery (CD) | Percentage of participants with Cesarean delivery (CD) | 5 minutes | |
| Primary | Deep venous thrombosis | diagnosed by imaging tools such as venous Doppler ultrasound of the lower limbs | 5 minutes | |
| Primary | Pulmonary embolism | diagnosed by imaging tools such as angio-CT scan of the thorax. | 5 minutes | |
| Primary | Pregnancy loss at less than 24 weeks' gestation | 5 minutes | ||
| Primary | Intrauterine Fetal Demise (IUFD) | Pregnancy loss at 24 weeks or more, or the delivery of a neonate weighing more than 500 g | 5 minutes | |
| Primary | Maternal death | Maternal death | 5 minutes | |
| Primary | Low birth weight | birth weight at less than 2500g | 5 minutes | |
| Primary | Number of participants with Neonatal intensive care unit (NICU) admission | Number of participants with Neonatal intensive care unit (NICU) admission | 5 minutes | |
| Primary | Percentage of participants with Neonatal intensive care unit (NICU) admission | Percentage of participants with Neonatal intensive care unit (NICU) admission | 5 minutes | |
| Primary | Number of participants with APGAR score (Activity, Pulse, Grimace, Appearance, Respiration score) at 5 minutes < 7: | The score minimum is 0 and maximum is 10. Higher score means better outcome. | 5 minutes | |
| Primary | Percentage of participants with APGAR score (Activity, Pulse, Grimace, Appearance, Respiration score) at 5 minutes < 7: | The score minimum is 0 and maximum is 10. Higher score means better outcome. | 5 minutes | |
| Primary | Number of participants with Respiratory distress at birth | Number of participants with Respiratory distress at birth | 5 minutes | |
| Primary | Percentage of participants with Respiratory distress at birth | Percentage of participants with Respiratory distress at birth | 5 minutes | |
| Primary | Neonatal death | 5 minutes | ||
| Secondary | Number of participants with Delivery < 32 weeks | 5 minutes | ||
| Secondary | Percentage of participants with Delivery < 32 weeks | 5 minutes | ||
| Secondary | Number of participants with Spontaneous delivery < 37 weeks | 5 minutes | ||
| Secondary | Percentage of participants with Spontaneous delivery < 37 weeks | 5 minutes | ||
| Secondary | Number of participants with Fetal distress | referred to bradycardia, recurrent late or variable deceleration on antepartum or intrapartum cardiotocogram. | 5 minutes | |
| Secondary | Percentage of participants with Fetal distress | referred to bradycardia, recurrent late or variable deceleration on antepartum or intrapartum cardiotocogram. | 5 minutes | |
| Secondary | Number of participants with Unscheduled cesarean delivery | 5 minutes | ||
| Secondary | Percentage of participants with Unscheduled cesarean delivery | 5 minutes | ||
| Secondary | Postpartum hemorrhage | defined as the estimated blood loss of > 500 mL | 5 minutes | |
| Secondary | Number of participants with Intraventricular hemorrhage | 5 minutes | ||
| Secondary | Percentage of participants with Intraventricular hemorrhage | 5 minutes | ||
| Secondary | Umbilical cord pH | 5 minutes | ||
| Secondary | Small for gestational age (SGA) | it refers to an estimated fetal weight of less than the 10th percentile | 5 minutes | |
| Secondary | Large for gestational age (LGA) | it refers to an estimated fetal weight of more than the 95th percentile | 5 minutes |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
| Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
| Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
| Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
| Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
| Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
| Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
| Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
| Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
| Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
| Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
| Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
| Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
| Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
| Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
| Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |